- Home
- SAVA vs LFT Comparison
SAVA vs LFT Comparison
Compare SAVA & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- LFT
- Stock Information
- Founded
- SAVA 1998
- LFT 2012
- Country
- SAVA United States
- LFT United States
- Employees
- SAVA N/A
- LFT N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- LFT Real Estate Investment Trusts
- Sector
- SAVA Health Care
- LFT Real Estate
- Exchange
- SAVA Nasdaq
- LFT Nasdaq
- Market Cap
- SAVA 102.4M
- LFT 109.9M
- IPO Year
- SAVA N/A
- LFT N/A
- Fundamental
- Price
- SAVA $2.16
- LFT $2.34
- Analyst Decision
- SAVA Hold
- LFT Hold
- Analyst Count
- SAVA 1
- LFT 2
- Target Price
- SAVA $2.00
- LFT N/A
- AVG Volume (30 Days)
- SAVA 607.2K
- LFT 145.0K
- Earning Date
- SAVA 11-06-2025
- LFT 08-08-2025
- Dividend Yield
- SAVA N/A
- LFT 10.30%
- EPS Growth
- SAVA N/A
- LFT N/A
- EPS
- SAVA N/A
- LFT 0.18
- Revenue
- SAVA N/A
- LFT $25,803,999.00
- Revenue This Year
- SAVA N/A
- LFT $139.76
- Revenue Next Year
- SAVA N/A
- LFT N/A
- P/E Ratio
- SAVA N/A
- LFT $12.95
- Revenue Growth
- SAVA N/A
- LFT N/A
- 52 Week Low
- SAVA $1.15
- LFT $2.05
- 52 Week High
- SAVA $33.98
- LFT $2.84
- Technical
- Relative Strength Index (RSI)
- SAVA 45.76
- LFT 59.57
- Support Level
- SAVA $2.12
- LFT $2.22
- Resistance Level
- SAVA $2.40
- LFT $2.25
- Average True Range (ATR)
- SAVA 0.10
- LFT 0.07
- MACD
- SAVA -0.01
- LFT 0.02
- Stochastic Oscillator
- SAVA 17.24
- LFT 92.12
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.